Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Immunotoxin therapy Clear all
Completed Phase 2 Interventional Results available

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02487979
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
149
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 19, 2026, 12:34 PM EDT
No Longer Available No phase listed Expanded access

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

NCT02715843
View directory record Official record
Conditions
Non-Hodgkin's B-cell Lymphoma
Interventions
MT-3724
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Results available

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

NCT04034238
View directory record Official record
Conditions
Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Interventions
LMB-100, Tofacitinib, Mesothelin Expression
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

NCT01829711
View directory record Official record
Conditions
Leukemia, Hairy Cell
Interventions
Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 19, 2026, 12:34 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Results available

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

NCT02798536
View directory record Official record
Conditions
Mesothelioma
Interventions
LMB-100, nab-paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 19, 2026, 12:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

NCT01087333
View directory record Official record
Conditions
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

NCT00077922
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic
Interventions
LMB-2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 19, 2026, 12:34 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

NCT00587457
View directory record Official record
Conditions
Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
Interventions
CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Indianapolis, Indiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

NCT00064779
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Oligoastrocytoma
Interventions
IL13-PE38QQR, targeted fusion protein therapy, surgery
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Results available

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

NCT00586924
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox (CAT 8015), CAT 8015 (Moxetumomab Pasudotox)
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 19, 2026, 12:34 PM EDT
Terminated Phase 3 Interventional Results available

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

NCT04128319
View directory record Official record
Conditions
Steroid-Refractory Acute Graft Versus Host Disease
Interventions
T-Guard
Drug
Lead sponsor
Xenikos
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
24
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

NCT01051934
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Adenocarcinoma
Interventions
SS1 (dsFv) PE38, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Cancer

NCT00006981
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

NCT02370160
View directory record Official record
Conditions
Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Lymphoma
Interventions
DT2219ARL
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 19, 2026, 12:34 PM EDT
Withdrawn Phase 1 Interventional

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00024115
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
BL22 immunotoxin, antibody therapy, biological response modifier therapy, immunotoxin therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 1Phase 2 Interventional

Immunotoxin Therapy in Treating Patients With Malignant Glioma

NCT00006268
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cintredekin besudotox, isolated perfusion, conventional surgery
Biological · Drug · Procedure
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 19, 2026, 12:34 PM EDT
Not listed Phase 1Phase 2 Interventional

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

NCT02990416
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
Biological · Radiation
Lead sponsor
Virogen Biotechnology Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 19, 2026, 12:34 PM EDT
Withdrawn Phase 1 Interventional

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

NCT05375825
View directory record Official record
Conditions
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant, Mesothelin (Msln)
Interventions
Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
Procedure · Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 19, 2026, 12:34 PM EDT
Suspended Phase 1 Interventional

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00077493
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy, monoclonal antibody therapy
Drug · Procedure
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 24 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 19, 2026, 12:34 PM EDT
Not listed Phase 1 Interventional

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

NCT00515892
View directory record Official record
Conditions
Leukemia, Non-Hodgkin's Lymphoma, NHL
Interventions
Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy, Antibody Therapy, Monoclonal Antibody Therapy
Drug · Procedure
Lead sponsor
Cambridge Antibody Technology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Beverly Hills, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Oct 19, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

NCT00080535
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
LMB-2
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 19, 2026, 12:34 PM EDT
Terminated Phase 1 Interventional

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

NCT01445392
View directory record Official record
Conditions
Mesothelioma
Interventions
Multicycle SS1P, Pemetrexed, Cisplatin, Single cycle SS1P
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 19, 2026, 12:34 PM EDT